Heart fat targeted: new drug combo may lower attack risk

NCT ID NCT07297589

Recruiting now Disease control Sponsor: Instituto Mexicano del Seguro Social Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two diabetes medications (SGLT2 inhibitors and GLP-1 agonists) to see if they can reduce epicardial fat—the fat around the heart—in people who recently had a heart attack. About 136 participants with type 2 diabetes and obesity will have their heart fat measured by CT scan at the start and after 12 months of treatment. The goal is to find a way to lower future heart risks by targeting this specific fat.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPICARDIAL FAT STEMI - ST ELEVATION MYOCARDIAL INFARCTION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Unidad Medica de Alta Especialidad No. 1, Bajío
RECRUITING

León, Guanajuato, 37260,, Mexico

Contact Email: •••••@•••••